

Literaturverzeichnis zum Varia-Beitrag

„Neutralisierende monoklonale Antikörper bei SARS-CoV-2-Infektionen“

von Dr. Johanna Erber, Dr. Roman Jakoubov, Universitätsprofessor Dr. Roland M. Schmid, Privatdozent Dr. Fabian Geisler, Privatdozent Dr. Christoph D. Spinner und Privatdozent Dr. Jochen Schneider

Bayerisches Ärzteblatt 12/2021, Seite 618 ff.

1. Agency EM. COVID-19 treatments [Available from: <https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-treatments>].
2. Aktualisierung BdSz, COVID-19-Impfempfehlung. d. Epidemiologisches Bulletin 43/2021.
3. O'Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan KC, Sarkar N, et al. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. The New England journal of medicine. 2021;385(13):1184-95.
4. Isa F, Forleo-Neto E, Meyer J, Zheng W, Rasmussen S, Armas D, et al. Repeat Subcutaneous Administration of REGEN-COV[®] in Adults is Well-Tolerated and Prevents the Occurrence of COVID-19. medRxiv. 2021:2021.11.10.21265889.
5. Agency EM. [Available from: https://www.ema.europa.eu/en/documents/rmp-summary/ronapreve-epar-risk-management-plan_en.pdf].
6. Institut RK. [Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Therapie/MAK-Infografik.pdf?__blob=publicationFile].
7. Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, et al. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. The New England journal of medicine. 2021;385(15):1382-92.
8. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. The New England journal of medicine. 2021.
9. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. The New England journal of medicine. 2021;384(3):238-51.
10. Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. The New England journal of medicine. 2021;384(3):229-37.
11. Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. Jama. 2021;325(7):632-44.
12. S3-Leitlinie - Empfehlungen zur stationären Therapie von Patienten mit COVID-19. 2021.
13. Rochweg B, Agarwal A, Siemieniuk RA, Agoritsas T, Lamontagne F, Askie L, et al. A living WHO guideline on drugs for covid-19. Bmj. 2020;370:m3379.
14. Robert Koch-Institut.
15. Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, et al. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021;9(9):Cd013825.
16. Group RC, Horby PW, Mafham M, Peto L, Campbell M, Pessoa-Amorim G, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv. 2021:2021.06.15.21258542.

17. Paul-Ehrlich-Institut. [Available from: https://www.pei.de/SharedDocs/Downloads/DE/newsroom/dossiers/regncov-2-fachinformation.pdf?__blob=publicationFile&v=5.
18. Prevention CfDca. [Available from: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2F covid-19%2Finfo-by-product%2Fclinical-considerations.html#antiviral-therapy.